COVID-19 Gov’t Contracts: KEI has obtained numerous contracts between the federal government and pharmaceutical companies regarding COVID-19 medical technologies via the Freedom of Information act. For these and other contracts, please see: https://www.keionline.org/covid-contracts. COVID-19 Vaccine Manufacturing: KEI has gathered data… Continue Reading →
Today the World Health Assembly (WHA) approved A72/A/CONF./2 Rev.1 as a resolution, titled “Improving the transparency of markets for medicines, vaccines, and other health products.” Link to the resolution: http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf When the text was made available, I sent out a… Continue Reading →
See https://keionline.org/transparency for links to research materials and blogs. Background Memo on Transparency Norms 2019. February 18. Note prepared for WHA negotiations on transparency resolution Examples of SEC disclosures Negotiating texts for WHA 72, on transparency. February 1, 2019. Draft… Continue Reading →
On Monday May 6, 2019, KEI gave the following intervention during the Department of Health and Human Services (HHS) Listening Session in advance of the Seventy-second World Health Assembly to be held in Geneva on May 20-28, 2019. KEI Statement… Continue Reading →
On Agenda item 11.7 – Access to medicines and vaccines, KEI offers the following comments on the transparency resolution. 1. Transparency should not be controversial. Policy makers and the public need to have better evidence in order to support policies… Continue Reading →
The WHO has scheduled two information negotiations on the WHA transparency resolution, in Geneva, for May 7 and 10. Below is the revised version of the proposed resolution, that will be discussed at these two meetings. Improving the transparency of… Continue Reading →
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading →
On 1 February 2019, Dr. Giulia Grillo, Italy’s Minister of Health, sent a letter to Dr. Tedros Adhanom Ghebreyesus, the Director General of the World Health Organization (WHO), with an attached “first draft” of a resolution on “Improving the transparency… Continue Reading →
The WHO Essential Medicines List is a major WHO tool used to expand access to medicines. In 2017, the WHO issued the 20th Essential Medicines List (EML) which was the 40th anniversary of the list. The WHO is currently in… Continue Reading →
KEI/HAI Interventions HAI/KEI intervention at the WHA69 on the Framework of Engagement with Non-State Actors HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement Interventions by Member States WHA 69: Colombian Minister of Health Calls on WHO… Continue Reading →